EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Durable Hematologic Response in Therapy-Related Myelodysplastic Syndrome During Nivolumab Treatment for Metastatic Melanoma: A Case Report

Fathima Nashfa M Hamza, Fatima Eltayeb, Mohammed Al Katari, Mohammed F K Ibrahim

Current Oncology · 13.08.2026 · 33 (8) · 476

DOI: 10.3390/curroncol33080476 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Current Oncology, online erschienen am 13.08.2026. Verfasst von Fathima Nashfa M Hamza und 3 weiteren Autor:innen. Beteiligte Einrichtung: Regional Cancer Care Northwest, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON P7B 6V4, Canada. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Melanoma, Nivolumab, Antineoplastic Agents, Immunological. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy is the standard first-line palliative treatment for metastatic melanoma; however, its role in myelodysplastic syndrome (MDS) remains uncertain. We report a case in which nivolumab, administered for metastatic melanoma, was associated with a marked improvement in concurrent treatment-related MDS. A 67-year-old man with a history of oligosecretory multiple myeloma developed transfusion-dependent MDS following autologous stem cell transplantation, requiring twice-weekly blood transfusions. He subsequently developed metastatic melanoma and was treated with single agent nivolumab to minimize treatment-related toxicity. Nivolumab effectively controlled the melanoma, and during treatment the patient experienced a durable hematologic response with sustained transfusion independence. At approximately two years of follow up, he remained transfusion-independent with stable peripheral blood counts, supporting the durability of the hematologic response. Although checkpoint inhibitors are not established therapies for therapy-related MDS and a causal relationship cannot be confirmed from a single case, the timing and sustained nature of the response are noteworthy. The patient experienced a significant improvement in quality of life with minimal adverse effects. This case adds to the limited literature on checkpoint inhibition in MDS and supports further investigation of its potential effects on hematologic recovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesMelanomaNivolumabAntineoplastic Agents, ImmunologicalHumansMaleAged

Stichwörter der Autor:innen

Myelodysplastic syndromecase reportcheckpoint inhibitorimmunotherapymelanomanivolumab

Substanzen

NivolumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Regional Cancer Care Northwest, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON P7B 6V4, Canada.
  • Wythenshawe Hospital, Manchester University NHS Foundation Trust, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK.
  • Division of Clinical Sciences, Northern Ontario School of Medicine University, Thunder Bay, ON P7B 5E1, Canada.

Zitieren

APA

Hamza, F. N. M., Eltayeb, F., Al Katari, M., & Ibrahim, M. F. K. (2026). Durable Hematologic Response in Therapy-Related Myelodysplastic Syndrome During Nivolumab Treatment for Metastatic Melanoma: A Case Report. Current Oncology, 33(8), 476. https://doi.org/10.3390/curroncol33080476

Vancouver

Hamza FNM, Eltayeb F, Al Katari M, Ibrahim MFK. Durable Hematologic Response in Therapy-Related Myelodysplastic Syndrome During Nivolumab Treatment for Metastatic Melanoma: A Case Report. Current Oncology. 2026;33(8):476. doi:10.3390/curroncol33080476

BibTeX
@article{Hamza2026,
  author = {Hamza, Fathima Nashfa M and Eltayeb, Fatima and Al Katari, Mohammed and Ibrahim, Mohammed F K},
  title = {Durable Hematologic Response in Therapy-Related Myelodysplastic Syndrome During Nivolumab Treatment for Metastatic Melanoma: A Case Report},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {8},
  pages = {476},
  doi = {10.3390/curroncol33080476}
}
Kostenlos starten →